Rate of microbiological contamination in vials of bevacizumab used for multiple intravitreal injections.
OBJECTIVE
A prospective pilot study was undertaken to determine the rate (if any) of microbiological contamination in vials of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) being accessed for multiple intravitreal injections.


METHODS
Twenty-one unfractionated, 100-mg (4 mL) vials of bevacizumab were used for 321 intravitreal injections. Each vial was accessed multiple times under sterile conditions. Upon completion of each vial, the residual contents were stored for a further 2 weeks before being sent for microbiological contamination studies.


RESULTS
No evidence of microbiological contamination was detected in 21 vials sent for assessment. Of 321 intravitreal injections performed, none was associated with any sign of endophthalmitis.


CONCLUSIONS
Using the same vial multiple times for intravitreal injections (stored for up to 4 weeks after opening) is a reasonable alternative to other methods of administering bevacizumab. Larger studies are required to determine the safety and efficacy of this practice.
From *City Eye Centre, Brisbane, and †University of Queensland, St. Lucia, Queensland, Australia.
Timothy C
TC
Smith
Lawrence R
LR
Lee